Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; Analysis of the IORRA database

References

• Yamanaka H, Seto Y, Tanaka E, Furuya T, Nakajima A, Ikari K, et al. Management of rheumatoid arthritis: the 2012 perspective. Mod Rheumatol. 2013;23(1):1–7.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Inoue E, Mannalithara A, Bennett M, Kamitsuji S, Taniguchi A, et al. Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study. Mod Rheumatol. 2010;20(1):46–53.
   PubMed Web of Science ®Google Scholar
• Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, et al. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model. Pharmacoeconomics. 2012;30(7):575–93.
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.
   PubMed Web of Science ®Google Scholar
• Tosh JC, Longworth LJ, Georege E. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals. Value Health. 2011;14(1):102–9.
   PubMed Web of Science ®Google Scholar
• Harrison MJ, Davies LM, Bansback NJ, Ingram M, Anis AH, Symmons DP. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol. 2008; 35(4):592–602.
   PubMed Web of Science ®Google Scholar
• Ariza-Ariza R, Hernandez-Cruz B, Carmona L, Dolores Ruiz-Montesions M, Ballina J, Navarro-Sarabia F; Costs and Quality of Life in Rheumatoid Arthritis Study Group. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol. Arthritis Rheum. 2006;55(5):751–6.
   PubMedGoogle Scholar
• Japanese EuroQol Translation Team. Journal of Health Care and Society. 1998;8:109–24
   Web of Science ®Google Scholar
• Fukuda W, Omoto A, Ohta T, Majima S, Kimura T, Tanaka T, et al. Low body mass index is associated with impaired quality of life in patients with rheumatoid arthritis. Int J Rheum Dis. 2013;16(3): 297–302.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol. 2006;16(2):75–6.
   PubMedGoogle Scholar
• Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the stanford health assessment questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;49(6):784–8.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Taniguchi A, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007;17(4):283–9.
   PubMedGoogle Scholar
• Yamanaka H, Inoue E, Tanaka E, Nakajima A, Taniguchi A, Terai C, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol. 2007;17(2):98–105.
   PubMedGoogle Scholar
• Seto Y, Tanaka E, Inoue E, Nakajima A, Taniguchi A, Momohara S, et al. Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database. Mod Rheumatol. 2011;21(6):579–93.
   PubMed Web of Science ®Google Scholar
• Momohara S, Inoue E, Ikari K, Yano K, Tokita A, Honjyo Y, et al. Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute. Mod Rheumatol. 2012;22(2):209–15.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observationaol cohort, IORRA. Scand J Rheumatol. 2010;39(5):360–7.
   PubMed Web of Science ®Google Scholar
• Linde L, Sørensen J, Østergaard M, Hørslev-Petersen K, Hetland ML. Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important? J Rheumatol. 2010;37(2):285–90.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol. 1997;36(7): 786–93.
   PubMedGoogle Scholar
• Russell AS, Conner-Spady B, Mintz A, Mallon C, Maksymowych WP. The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. J Rheumatol. 2003;30(5):941–7.
   PubMed Web of Science ®Google Scholar
• Conner-Spady B, Suarez-Almazor ME. Variation in the estimation of quality-adjusted life-years by different preference-based instruments. Med Care. 2003;41(7):791–801.
   PubMed Web of Science ®Google Scholar
• Luo N, Chew LH, Fong KY, Koh DR, Ng SC, Yoon KH, et al. A comparison of the EuroQol-5D and the Health Utilities Index mark 3 in patients with rheumatic disease. J Rheumatol. 2003;30(10): 2268–74.
   PubMed Web of Science ®Google Scholar
• Harrison MJ, Tricker KJ, Davies L, Hassell A, Dawes P, Scott DL, et al. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. J Rheumatol. 2005;32(12):2330–6.
   PubMed Web of Science ®Google Scholar
• Linde L, Sørensen J, Østergaard M, Hetland ML. Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice. J Rheumatol. 2010;40(9):1479–86.
   Google Scholar
• van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, de Vries-Bouwstra JK, Hazes JM, Kerstens PJ, et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2009;61(3):291–9.
   PubMedGoogle Scholar
• Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis. 2004;63(1):4–10.
   PubMed Web of Science ®Google Scholar